The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Phase II Study of Erlotinib in Patients With Advanced Biliary Cancer
Abstract
Purpose: Epidermal growth factor receptor/human epidermal growth factor receptor 1 and ligand expression is common in biliary cancers (BILI) and may be associated with worse outcome. The primary objective of this study was to determine the proportion of patients with advanced BILI who were progression-free at 6 months. Methods: Patients with either unresectable or metastatic disease were studied. Only one prior systemic or locoregional therapy was allowed. Erlotinib was administered continuously at a dose of 150 mg per day orally. Results: Forty-two patients with BILI were enrolled. The median age was 67 years (range, 33 to 82 years). Fifty-two percent of patients had Eastern Cooperative Oncology Group performance status of 1. Fifty-seven percent of patients had received prior chemotherapy for advanced BILI. HER1/EGFR expression by immunohistochemistry in tumor cells was detected in 29 (81%) of the 36 assessable patients. Seven of the patients (17%; 95% CI, 7% to 31%) were progression free at 6 months. Three patients had partial response by Response Evaluation Criteria in Solid Tumors Group classification of duration 4, 4, and 14 months, respectively. All responding patients had mild (grade 1/2) skin rash and two patients had positive tumoral HER1/EGFR expression. Three patients (7%) had toxicity-related dose reductions of erlotinib due to grade 2/3 skin rash. Conclusion: Results suggest a therapeutic benefit for EGFR blockade with erlotinib in patients with biliary cancer. Additional studies with erlotinib as a single agent and in combination with other targeted agents are warranted in this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
The Epidemiology of Cholangiocarcinoma
Shaib, Y., & El-Serag, H. (2004) · Seminars in Liver Disease · doi:10.1055/s-2004-828889 · Cited by 1,132
The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy
Woodburn, J. R. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00045-x · Cited by 827
Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer
Philip, P. A., Mahoney, M. R., Allmer, C., Thomas, J., Pitot, H. C., Kim, G., Donehower, R. C., Fitch, T., Picus, J., & Erlichman, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.696 · Cited by 462
Self-citationCholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy
Sirica, A. E. (2005) · Hepatology · doi:10.1002/hep.20537 · Cited by 315
Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial
Knox, J. J., Hedley, D. W., Oza, A. M., Feld, R., Siu, L. L., Chen, E. X., Nematollahi, M., Pond, G. R., Zhang, J., & Moore, M. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.51.008 · Cited by 305
A Review and Update on Cholangiocarcinoma
Olnes, M. J., & Erlich, R. (2004) · Oncology · doi:10.1159/000077991 · Cited by 266
Bile acids activate EGF receptor via a TGF-α-dependent mechanism in human cholangiocyte cell lines
Werneburg, N. W., Yoon, J., Higuchi, H., & Gores, G. J. (2003) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00536.2002 · Cited by 157
Confidence Intervals for a Binomial Parameter Based on Multistage Tests
Duffy, D. E., & Santner, T. J. (1987) · Biometrics · doi:10.2307/2531951 · Cited by 143
Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells
Yoon, J., Gwak, G., Lee, H.-S., Bronk, S. F., Werneburg, N. W., & Gores, G. J. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.07.016 · Cited by 132
Cited by
New Horizons for Precision Medicine in Biliary Tract Cancers
Valle, J. W., Lamarca, A., Goyal, L., Barriuso, J., & Zhu, A. X. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0245 · Cited by 626
Tse, R. V., Hawkins, M., Lockwood, G., Kim, J. J., Cummings, B., Knox, J., Sherman, M., & Dawson, L. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3529 · Cited by 589
Andersen, J. B., Spee, B., Blechacz, B. R., Avital, I., Komuta, M., Barbour, A., Conner, E. A., Gillen, M. C., Roskams, T., Roberts, L. R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.005 · Cited by 552
Lee, J., Park, S. H., Chang, H.-M., Kim, J. S., Choi, H. J., Lee, M. A., Chang, J. S., Jeung, H. C., Kang, J. H., Lee, H. W., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70301-1 · Cited by 478
Targeted anti-mitotic therapies: can we improve on tubulin agents?
Jackson, J. R., Patrick, D. R., Dar, M. M., & Huang, P. S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2049 · Cited by 473
Metadata
- Authors
- Philip, P. A., Mahoney, M. R., Allmer, C., Thomas, J., Pitot, H. C., Kim, G., Donehower, R. C., Fitch, T., Picus, J., & Erlichman, C.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-07-01
- Volume
- 24
- Issue
- 19
- Pages
- 3069-3074
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2118520585
- Cited by
- 318
- References
- 16
- FWCI
- 21.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.